immune checkpoint inhibitor

You have access
Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors
NAR BAHADUR KATUWAL, NAHEE PARK, KAMAL PANDEY, MIN SIL KANG, SA DEOK HONG, MITHUN GHOSH, SEUL-GI KIM, YOUNG BIN CHO, JIN HUR, SEUNG KI KIM and YONG WHA MOON

Anticancer Research January 2023, 43 (1) 85-95; DOI: https://doi.org/10.21873/anticanres.16137
You have access
Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation
SOU HATTORI, SHINICHIRO OKAUCHI, YUIKA SASATANI, GEN OHARA, KUNIHIKO MIYAZAKI, SHINYA SATO, TAKAHIDE KODAMA, TOSHIHIRO SHIOZAWA, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research September 2022, 42 (9) 4589-4595; DOI: https://doi.org/10.21873/anticanres.15962
You have access
Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO

Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851
You have access
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA

Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854
Open Access
Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer
EISUKE BOOKA, HIROTOSHI KIKUCHI, RYOMA HANEDA, WATARU SONEDA, SANSHIRO KAWATA, TOMOHIRO MURAKAMI, TOMOHIRO MATSUMOTO, YOSHIHIRO HIRAMATSU and HIROYA TAKEUCHI

Anticancer Research June 2022, 42 (6) 2977-2987; DOI: https://doi.org/10.21873/anticanres.15781
You have access
Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer
CARSTEN NIEDER, SIV GYDA AANES and ELLINOR C. HAUKLAND

Anticancer Research June 2022, 42 (6) 3061-3066; DOI: https://doi.org/10.21873/anticanres.15793
You have access
Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer
MOTOHIRO FUJIWARA, RYO FUJIWARA, TETSUYA URASAKI, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA

Anticancer Research April 2022, 42 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.15685
You have access
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
CHIARA CICCARESE, ROBERTO IACOVELLI, SEBASTIANO BUTI, FRANCESCA PRIMI, SERENA ASTORE, FRANCESCO MASSARI, MIRIAM GRAZIA FERRARA, GIUSEPPE PALERMO, NAZARIO FOSCHI, VALERIO IACOVELLI, ERNESTO ROSSI, GIOVANNI SCHINZARI, PIERLUIGI BOVE, PIERFRANCESCO BASSI, EMILIO BRIA and GIAMPAOLO TORTORA

Anticancer Research March 2022, 42 (3) 1487-1493; DOI: https://doi.org/10.21873/anticanres.15620
You have access
Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma
YUKARI BANDO, JUNYA FURUKAWA, YASUYOSHI OKAMURA, TAKUTO HARA, TOMOAKI TERAKAWA, YUZO NAKANO and MASATO FUJISAWA

Anticancer Research February 2022, 42 (2) 973-979; DOI: https://doi.org/10.21873/anticanres.15557
You have access
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA

Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442

Main menu

User menu

Search

immune checkpoint inhibitor

Pages